Kings Point Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-400
| Closed | -$28K | – | 642 |
|
|
2021
Q3 | $28K | Hold |
400
| – | – | ﹤0.01% | 440 |
|
|
2021
Q2 | $28K | Hold |
400
| – | – | ﹤0.01% | 421 |
|
|
2021
Q1 | $26K | Sell |
400
-375
| -48% | -$24.2K | ﹤0.01% | 422 |
|
|
2020
Q4 | $45K | Sell |
775
-1,200
| -61% | -$72.4K | ﹤0.01% | 326 |
|
|
2020
Q3 | $125K | Buy |
1,975
+1,468
| +290% | +$102K | 0.02% | 216 |
|
|
2020
Q2 | $39K | Sell |
507
-13
| -3% | -$996 | 0.01% | 299 |
|
|
2020
Q1 | $39K | Sell |
520
-780
| -60% | -$53.9K | 0.01% | 304 |
|
|
2019
Q4 | $84K | Buy |
1,300
+831
| +177% | +$54.1K | 0.01% | 255 |
|
|
2019
Q3 | $30K | Buy |
469
+69
| +17% | +$4.51K | 0.01% | 354 |
|
|
2019
Q2 | $27K | Hold |
400
| – | – | ﹤0.01% | 320 |
|
|
2019
Q1 | $26K | Hold |
400
| – | – | 0.01% | 289 |
|
|
2018
Q4 | $25K | Sell |
400
-46
| -10% | -$3.21K | 0.01% | 290 |
|
|
2018
Q3 | $34K | Buy |
446
+46
| +12% | +$3.47K | 0.01% | 276 |
|
|
2018
Q2 | $28K | Hold |
400
| – | – | 0.01% | 290 |
|
|
2018
Q1 | $30K | Hold |
400
| – | – | 0.01% | 285 |
|
|
2017
Q4 | $29K | Sell |
400
-815
| -67% | -$61.9K | 0.01% | 283 |
|
|
2017
Q3 | $98K | Buy |
1,215
+815
| +204% | +$62.3K | 0.02% | 182 |
|
|
2017
Q2 | $28K | Sell |
400
-350
| -47% | -$23.3K | 0.01% | 261 |
|
|
2017
Q1 | $51K | Sell |
750
-300
| -29% | -$21.1K | 0.01% | 217 |
|
|
2016
Q4 | $75K | Hold |
1,050
| – | – | 0.02% | 178 |
|
|
2016
Q3 | $83K | Hold |
1,050
| – | – | 0.02% | 156 |
|
|
2016
Q2 | $88K | Hold |
1,050
| – | – | 0.02% | 159 |
|
|
2016
Q1 | $96K | Sell |
1,050
-91
| -8% | -$8.21K | 0.02% | 151 |
|
|
2015
Q4 | $115K | Hold |
1,141
| – | – | 0.03% | 146 |
|
|
2015
Q3 | $112K | Buy |
1,141
+14
| +1% | +$1.55K | 0.03% | 162 |
|
|
2015
Q2 | $132K | Sell |
1,127
-68
| -6% | -$7.43K | 0.03% | 151 |
|
|
2015
Q1 | $117K | Buy |
1,195
+8
| +0.7% | +$812 | 0.03% | 157 |
|
|
2014
Q4 | $112K | Sell |
1,187
-932
| -44% | -$96.4K | 0.03% | 144 |
|
|
2014
Q3 | $226K | Buy |
2,119
+1,219
| +135% | +$119K | 0.07% | 105 |
|
|
2014
Q2 | $75K | Buy |
900
+100
| +13% | +$7.78K | 0.02% | 154 |
|
|
2014
Q1 | $57K | Buy |
800
+500
| +167% | +$39.2K | 0.02% | 166 |
|
|
2013
Q4 | $23K | Hold |
300
| – | – | 0.01% | 212 |
|
|
2013
Q3 | $19K | Hold |
300
| – | – | 0.01% | 223 |
|
|
2013
Q2 | $15K | Buy |
+300
| New | +$15.6K | 0.01% | 247 |
|
Other funds holding GILD
Kings Point Capital Management's GILD Position: Q4 2021 in Review
Kings Point Capital Management sold out of Gilead Sciences (GILD) in Q4 2021, closing a stake of 400 shares — an estimated $28K sold.
Kings Point Capital Management first reported a position in GILD in Q2 2013 and held it in 34 quarters. The position peaked at $226K in Q3 2014. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.
- Kings Point Capital Management reported no remaining Gilead Sciences position as of Q4 2021 after selling out during the quarter.
- Kings Point Capital Management sold 400 Gilead Sciences shares in Q4 2021, an estimated $28K.
- Kings Point Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 34 quarters.
- Kings Point Capital Management's Gilead Sciences position peaked at $226K in Q3 2014.
- 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.
Based on Kings Point Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.